Details of the Drug

General Information of Drug (ID: DMOBIKY)

Drug Name
Bexarotene
Synonyms
Bexaroteno; Bexarotenum; Targret; Targretin; Targretyn; Targrexin; Bexarotene [USAN]; Elan brand of bexarotene;Ligand brand of bexarotene; LG 1069; LG100069; LG1069; LG69 compound; LGD 1069; LGD1069; LG-100069; LGD-1069; Targretin (TN); Targretin-gel; Bexarotene (USAN/INN); P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; 9RA
Indication
Disease Entry ICD 11 Status REF
Cutaneous T-cell lymphoma 2B01 Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 348.5
Topological Polar Surface Area (xlogp) 7.6
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination
0.01% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 28.6961 micromolar/kg/day [5]
Chemical Identifiers
Formula
C24H28O2
IUPAC Name
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
Canonical SMILES
CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C
InChI
InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
InChIKey
NAVMQTYZDKMPEU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
82146
ChEBI ID
CHEBI:50859
CAS Number
153559-49-0
DrugBank ID
DB00307
TTD ID
D0N0RU
INTEDE ID
DR0208
ACDINA ID
D00068

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Retinoic acid receptor RXR-alpha (RXRA) TT6PEUO RXRA_HUMAN Modulator [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Bexarotene
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Bexarotene and Methoxsalen. Mycosis fungoides [2B01] [33]
Coadministration of a Drug Treating the Disease Different from Bexarotene (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Bexarotene and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [33]
Methylergonovine DMBEX4O Moderate Increased metabolism of Bexarotene caused by Methylergonovine mediated induction of CYP450 enzyme. Abortion [JA00] [33]
Repaglinide DM5SXUV Moderate Increased metabolism of Bexarotene caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [34]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Bexarotene and Thioguanine. Acute myeloid leukaemia [2A60] [35]
Ivosidenib DM8S6T7 Minor Increased metabolism of Bexarotene caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [36]
Midostaurin DMI6E0R Moderate Increased metabolism of Bexarotene caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [37]
Oliceridine DM6MDCF Moderate Increased metabolism of Bexarotene caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [38]
Mitotane DMU1GX0 Minor Increased metabolism of Bexarotene caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [36]
Donepezil DMIYG7Z Moderate Increased metabolism of Bexarotene caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [39]
Ivabradine DM0L594 Moderate Increased metabolism of Bexarotene caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [40]
Bepridil DM0RKS4 Moderate Increased metabolism of Bexarotene caused by Bepridil mediated induction of CYP450 enzyme. Angina pectoris [BA40] [40]
Dronedarone DMA8FS5 Moderate Increased metabolism of Bexarotene caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [41]
Nifedipine DMSVOZT Moderate Increased metabolism of Bexarotene caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [40]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Bexarotene and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [42]
Buspirone DMBS632 Moderate Increased metabolism of Bexarotene caused by Buspirone mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [43]
Clorazepate DMC3JST Moderate Increased metabolism of Bexarotene caused by Clorazepate mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [40]
Alprazolam DMC7XDN Moderate Increased metabolism of Bexarotene caused by Alprazolam mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [40]
Methylphenobarbital DMDSWAG Minor Increased metabolism of Bexarotene caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [44]
Montelukast DMD157S Moderate Increased metabolism of Bexarotene caused by Montelukast mediated induction of CYP450 enzyme. Asthma [CA23] [45]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Bexarotene and Roflumilast. Asthma [CA23] [40]
Tindamax DM3OWT4 Moderate Increased metabolism of Bexarotene caused by Tindamax mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [40]
Telithromycin DMZ4P3A Moderate Increased metabolism of Bexarotene caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [46]
Cariprazine DMJYDVK Moderate Increased metabolism of Bexarotene caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [40]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Bexarotene and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [47]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Bexarotene caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
Lapatinib DM3BH1Y Moderate Increased metabolism of Bexarotene caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
LY2835219 DM93VBZ Moderate Increased metabolism of Bexarotene caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [49]
Exemestane DM9HPW3 Moderate Increased metabolism of Bexarotene caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [50]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Bexarotene caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [51]
Palbociclib DMD7L94 Moderate Increased metabolism of Bexarotene caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
Alpelisib DMEXMYK Moderate Increased metabolism of Bexarotene caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [52]
Letrozole DMH07Y3 Moderate Increased metabolism of Bexarotene caused by Letrozole mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Bexarotene caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [51]
Tamoxifen DMLB0EZ Moderate Increased metabolism of Bexarotene caused by Tamoxifen mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [53]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Bexarotene caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Toremifene DMQYUWG Moderate Increased metabolism of Bexarotene caused by Toremifene mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [55]
Bosutinib DMTI8YE Moderate Increased metabolism of Bexarotene caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [56]
Estradiol DMUNTE3 Moderate Increased metabolism of Bexarotene caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [51]
Atorvastatin DMF28YC Moderate Increased metabolism of Bexarotene caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [57]
Macitentan DMP79A1 Moderate Increased metabolism of Bexarotene caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [58]
Secobarbital DM14RF5 Minor Increased metabolism of Bexarotene caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [36]
PF-04449913 DMSB068 Moderate Increased metabolism of Bexarotene caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [59]
Phenylbutazone DMAYL0T Minor Increased metabolism of Bexarotene caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [36]
Irinotecan DMP6SC2 Moderate Increased metabolism of Bexarotene caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [60]
Drospirenone DM1A9W3 Major Increased metabolism of Bexarotene caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [61]
Levonorgestrel DM1DP7T Major Increased metabolism of Bexarotene caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [61]
Ulipristal DMBNI20 Moderate Increased metabolism of Bexarotene caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [40]
Mestranol DMG3F94 Major Increased metabolism of Bexarotene caused by Mestranol mediated induction of CYP450 enzyme. Contraceptive management [QA21] [62]
Norgestimate DMYP4XC Major Increased metabolism of Bexarotene caused by Norgestimate mediated induction of CYP450 enzyme. Contraceptive management [QA21] [62]
Levobupivacaine DM783CH Minor Increased metabolism of Bexarotene caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [63]
Alfentanil DMVO0UB Moderate Increased metabolism of Bexarotene caused by Alfentanil mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [64]
Nimodipine DMQ0RKZ Moderate Increased metabolism of Bexarotene caused by Nimodipine mediated induction of CYP450 enzyme. Coronary vasospastic disease [BA85] [40]
Methadone DMTW6IU Moderate Increased metabolism of Bexarotene caused by Methadone mediated induction of CYP450 enzyme. Cough [MD12] [38]
Osilodrostat DMIJC9X Moderate Increased metabolism of Bexarotene caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [65]
Aminoglutethimide DMWFHMZ Minor Increased metabolism of Bexarotene caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [36]
Ivacaftor DMZC1HS Moderate Increased metabolism of Bexarotene caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [66]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Bexarotene caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [67]
Vilazodone DM4LECQ Moderate Increased metabolism of Bexarotene caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [68]
Vortioxetine DM6F1PU Moderate Increased metabolism of Bexarotene caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [69]
Trazodone DMK1GBJ Moderate Increased metabolism of Bexarotene caused by Trazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [40]
Griseofulvin DMK54YG Minor Increased metabolism of Bexarotene caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [36]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Bexarotene caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [70]
Oxybutynine DMJPBAX Moderate Increased metabolism of Bexarotene caused by Oxybutynine mediated induction of CYP450 enzyme. Discovery agent [N.A.] [40]
Oestradiol valerate and dienogest DMZK0FQ Major Increased metabolism of Bexarotene caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [62]
Zonisamide DM0DTF7 Moderate Increased metabolism of Bexarotene caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [71]
Primidone DM0WX6I Minor Increased metabolism of Bexarotene caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Felbamate DM1V5ZS Minor Increased metabolism of Bexarotene caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Oxcarbazepine DM5PU6O Minor Increased metabolism of Bexarotene caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Ethosuximide DMDZ9LT Moderate Increased metabolism of Bexarotene caused by Ethosuximide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [40]
Cenobamate DMGOVHA Minor Increased metabolism of Bexarotene caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Tiagabine DMKSQG0 Moderate Increased metabolism of Bexarotene caused by Tiagabine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [40]
Stiripentol DMMSDOY Moderate Decreased metabolism of Bexarotene caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [72]
Fosphenytoin DMOX3LB Minor Increased metabolism of Bexarotene caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Clonazepam DMTO13J Moderate Increased metabolism of Bexarotene caused by Clonazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [40]
Rufinamide DMWE60C Minor Increased metabolism of Bexarotene caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Phenobarbital DMXZOCG Minor Increased metabolism of Bexarotene caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Carbamazepine DMZOLBI Minor Increased metabolism of Bexarotene caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Eslicarbazepine DMZREFQ Minor Increased metabolism of Bexarotene caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Bexarotene and Cannabidiol. Epileptic encephalopathy [8A62] [40]
Nicardipine DMCDYW7 Moderate Increased metabolism of Bexarotene caused by Nicardipine mediated induction of CYP450 enzyme. Essential hypertension [BA00] [40]
Praziquantel DMOU1PK Moderate Increased metabolism of Bexarotene caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [73]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Bexarotene caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [74]
Tazemetostat DMWP1BH Moderate Increased metabolism of Bexarotene caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [75]
Solifenacin DMG592Q Moderate Increased metabolism of Bexarotene caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [76]
Mirabegron DMS1GYT Minor Increased metabolism of Bexarotene caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [77]
Caspofungin DMGQIPT Moderate Increased metabolism of Bexarotene caused by Caspofungin mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [78]
Cisapride DMY7PED Moderate Increased metabolism of Bexarotene caused by Cisapride mediated induction of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [40]
Ripretinib DM958QB Moderate Increased metabolism of Bexarotene caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [33]
Avapritinib DMK2GZX Moderate Increased metabolism of Bexarotene caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [40]
Sulfinpyrazone DMEV954 Minor Increased metabolism of Bexarotene caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [36]
Ergotamine DMKR3C5 Moderate Increased metabolism of Bexarotene caused by Ergotamine mediated induction of CYP450 enzyme. Headache [8A80-8A84] [33]
Boceprevir DMBSHMF Moderate Increased metabolism of Bexarotene caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [79]
Telaprevir DMMRV29 Moderate Increased metabolism of Bexarotene caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [79]
Rifampin DMA8J1G Minor Increased metabolism of Bexarotene caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [44]
Rifapentine DMCHV4I Minor Increased metabolism of Bexarotene caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [36]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Bexarotene and Brentuximab vedotin. Hodgkin lymphoma [2B30] [80]
MK-1439 DM215WE Moderate Increased metabolism of Bexarotene caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [81]
Delavirdine DM3NF5G Moderate Increased metabolism of Bexarotene caused by Delavirdine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [82]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Bexarotene caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Fostemsavir DM50ILT Minor Increased metabolism of Bexarotene caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Tipranavir DM8HJX6 Moderate Increased metabolism of Bexarotene caused by Tipranavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Efavirenz DMC0GSJ Moderate Increased metabolism of Bexarotene caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Dolutegravir DMCZGRE Minor Increased metabolism of Bexarotene caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [86]
Saquinavir DMG814N Moderate Increased metabolism of Bexarotene caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Etravirine DMGV8QU Minor Increased metabolism of Bexarotene caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Bexarotene caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [33]
Amprenavir DMLMXE0 Moderate Increased metabolism of Bexarotene caused by Amprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Darunavir DMN3GCH Moderate Increased metabolism of Bexarotene caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Atazanavir DMSYRBX Moderate Increased metabolism of Bexarotene caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Maraviroc DMTL94F Moderate Increased metabolism of Bexarotene caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [33]
Simvastatin DM30SGU Moderate Increased metabolism of Bexarotene caused by Simvastatin mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [40]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Bexarotene and Mipomersen. Hyper-lipoproteinaemia [5C80] [87]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Bexarotene and Teriflunomide. Hyper-lipoproteinaemia [5C80] [88]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Bexarotene and BMS-201038. Hyper-lipoproteinaemia [5C80] [89]
Nisoldipine DM7ISKJ Moderate Increased metabolism of Bexarotene caused by Nisoldipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [40]
Levamlodipine DM92S6N Moderate Increased metabolism of Bexarotene caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [40]
Diltiazem DMAI7ZV Moderate Increased metabolism of Bexarotene caused by Diltiazem mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [90]
Amlodipine DMBDAZV Moderate Increased metabolism of Bexarotene caused by Amlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [40]
Felodipine DMOSW35 Moderate Increased metabolism of Bexarotene caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [40]
Tolvaptan DMIWFRL Moderate Increased metabolism of Bexarotene caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [40]
Fludrocortisone DMUDIR8 Moderate Increased metabolism of Bexarotene caused by Fludrocortisone mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [40]
Suvorexant DM0E6S3 Moderate Increased metabolism of Bexarotene caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [91]
Amobarbital DM0GQ8N Minor Increased metabolism of Bexarotene caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [36]
Ramelteon DM7IW9J Moderate Increased metabolism of Bexarotene caused by Ramelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [92]
Eszopiclone DM8RZ9H Moderate Increased metabolism of Bexarotene caused by Eszopiclone mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [93]
Triazolam DMETYK5 Moderate Increased metabolism of Bexarotene caused by Triazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [40]
Pentobarbital DMFNH7L Minor Increased metabolism of Bexarotene caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [36]
Zaleplon DMGFWSM Minor Increased metabolism of Bexarotene caused by Zaleplon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [94]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Bexarotene caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [95]
ITI-007 DMUQ1DO Major Increased metabolism of Bexarotene caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [96]
Zolpidem DMWOSKJ Moderate Increased metabolism of Bexarotene caused by Zolpidem mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [40]
Estazolam DMZGXUM Moderate Increased metabolism of Bexarotene caused by Estazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [40]
Naloxegol DML0B41 Moderate Increased metabolism of Bexarotene caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [97]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Bexarotene and Methotrexate. Leukaemia [2A60-2B33] [40]
Pemigatinib DM819JF Moderate Increased metabolism of Bexarotene caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [40]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Bexarotene and Denosumab. Low bone mass disorder [FB83] [98]
Crizotinib DM4F29C Moderate Increased metabolism of Bexarotene caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [99]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Bexarotene and Porfimer Sodium. Lung cancer [2C25] [100]
Erlotinib DMCMBHA Moderate Increased metabolism of Bexarotene caused by Erlotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [101]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Bexarotene caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [102]
PF-06463922 DMKM7EW Minor Increased metabolism of Bexarotene caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [36]
Osimertinib DMRJLAT Moderate Increased metabolism of Bexarotene caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [103]
Capmatinib DMYCXKL Moderate Increased metabolism of Bexarotene caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [104]
Selpercatinib DMZR15V Moderate Increased metabolism of Bexarotene caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [40]
Halofantrine DMOMK1V Moderate Increased metabolism of Bexarotene caused by Halofantrine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [40]
Quinine DMSWYF5 Moderate Increased metabolism of Bexarotene caused by Quinine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [40]
Mefloquine DMWT905 Moderate Increased metabolism of Bexarotene caused by Mefloquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [105]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Bexarotene and Idelalisib. Mature B-cell leukaemia [2A82] [106]
GDC-0199 DMH0QKA Moderate Increased metabolism of Bexarotene caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [107]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Bexarotene caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [108]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Bexarotene and Clofarabine. Mature B-cell lymphoma [2A85] [109]
Ibrutinib DMHZCPO Moderate Increased metabolism of Bexarotene caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [110]
Vincristine DMINOX3 Moderate Increased metabolism of Bexarotene caused by Vincristine mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [40]
Vemurafenib DM62UG5 Moderate Increased metabolism of Bexarotene caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [111]
Selumetinib DMC7W6R Moderate Increased metabolism of Bexarotene caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [112]
LGX818 DMNQXV8 Moderate Increased metabolism of Bexarotene caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [113]
Dabrafenib DMX6OE3 Minor Increased metabolism of Bexarotene caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [36]
Estrone DM5T6US Moderate Increased metabolism of Bexarotene caused by Estrone mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [51]
Ethinyl estradiol DMODJ40 Major Increased metabolism of Bexarotene caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [62]
Nitisinone DMVS9WQ Moderate Increased metabolism of Bexarotene caused by Nitisinone mediated induction of CYP450 enzyme. Metabolism inborn error [5C50] [40]
Dihydroergotamine DM5IKUF Moderate Increased metabolism of Bexarotene caused by Dihydroergotamine mediated induction of CYP450 enzyme. Migraine [8A80] [33]
Ubrogepant DM749I3 Moderate Increased metabolism of Bexarotene caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [114]
Exjade DMHPRWG Minor Increased metabolism of Bexarotene caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [36]
Flibanserin DM70DTN Moderate Increased metabolism of Bexarotene caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [115]
Midazolam DMXOELT Moderate Increased metabolism of Bexarotene caused by Midazolam mediated induction of CYP450 enzyme. Mood/affect symptom [MB24] [40]
Panobinostat DM58WKG Moderate Increased metabolism of Bexarotene caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [116]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Bexarotene and Tecfidera. Multiple sclerosis [8A40] [117]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Bexarotene and Siponimod. Multiple sclerosis [8A40] [33]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Bexarotene and Fingolimod. Multiple sclerosis [8A40] [118]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Bexarotene and Ocrelizumab. Multiple sclerosis [8A40] [119]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Bexarotene and Ozanimod. Multiple sclerosis [8A40] [40]
Rifabutin DM1YBHK Minor Increased metabolism of Bexarotene caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [36]
Fedratinib DM4ZBK6 Moderate Increased metabolism of Bexarotene caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [40]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Bexarotene caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [120]
Dasatinib DMJV2EK Moderate Increased metabolism of Bexarotene caused by Dasatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [33]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Bexarotene and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [121]
Modafinil DMYILBE Moderate Increased metabolism of Bexarotene caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [122]
Rolapitant DM8XP26 Moderate Increased metabolism of Bexarotene caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [123]
Granisetron DMIUW25 Moderate Increased metabolism of Bexarotene caused by Granisetron mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [40]
E-2007 DMJDYNQ Moderate Increased metabolism of Bexarotene caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [40]
Entrectinib DMMPTLH Moderate Increased metabolism of Bexarotene caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [124]
Levomethadyl Acetate DM06HG5 Major Increased metabolism of Bexarotene caused by Levomethadyl Acetate mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [125]
S-297995 DM26IH8 Moderate Increased metabolism of Bexarotene caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [40]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Bexarotene caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [126]
Butorphanol DM5KYPJ Moderate Increased metabolism of Bexarotene caused by Butorphanol mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [38]
Buprenorphine DMPRI8G Moderate Increased metabolism of Bexarotene caused by Buprenorphine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [127]
Hydrocodone DMQ2JO5 Moderate Increased metabolism of Bexarotene caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [38]
Oxycodone DMXLKHV Moderate Increased metabolism of Bexarotene caused by Oxycodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [38]
Albendazole DMYZ57N Moderate Increased metabolism of Bexarotene caused by Albendazole mediated induction of CYP450 enzyme. Parasitic worm infestation [1F90] [40]
Pimavanserin DMR7IVC Moderate Increased metabolism of Bexarotene caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [128]
Abametapir DM2RX0I Moderate Decreased metabolism of Bexarotene caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [129]
Macimorelin DMQYJIR Moderate Increased metabolism of Bexarotene caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [130]
Lefamulin DME6G97 Moderate Increased metabolism of Bexarotene caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [131]
Prednisone DM2HG4X Moderate Increased metabolism of Bexarotene caused by Prednisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [40]
Betamethasone DMAHJEF Moderate Increased metabolism of Bexarotene caused by Betamethasone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [40]
Hydrocortisone DMGEMB7 Moderate Increased metabolism of Bexarotene caused by Hydrocortisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [40]
Ergonovine DM0VEC1 Moderate Increased metabolism of Bexarotene caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [33]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Bexarotene caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [132]
Progesterone DMUY35B Moderate Increased metabolism of Bexarotene caused by Progesterone mediated induction of CYP450 enzyme. Preterm labour/delivery [JB00] [51]
Enzalutamide DMGL19D Moderate Increased metabolism of Bexarotene caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [133]
Darolutamide DMV7YFT Moderate Increased metabolism of Bexarotene caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [134]
Silodosin DMJSBT6 Moderate Increased metabolism of Bexarotene caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [33]
Dutasteride DMQ4TJK Moderate Increased metabolism of Bexarotene caused by Dutasteride mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [40]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Bexarotene and Verteporfin. Psoriasis [EA90] [40]
Apremilast DMTWS9E Moderate Increased metabolism of Bexarotene caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [135]
Bosentan DMIOGBU Minor Increased metabolism of Bexarotene caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [36]
Riociguat DMXBLMP Moderate Increased metabolism of Bexarotene caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [136]
Everolimus DM8X2EH Moderate Increased metabolism of Bexarotene caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [33]
Axitinib DMGVH6N Moderate Increased metabolism of Bexarotene caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [137]
Temsirolimus DMS104F Moderate Increased metabolism of Bexarotene caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [33]
Sorafenib DMS8IFC Moderate Increased metabolism of Bexarotene caused by Sorafenib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [138]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Bexarotene and Canakinumab. Rheumatoid arthritis [FA20] [139]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Bexarotene and Rilonacept. Rheumatoid arthritis [FA20] [139]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Bexarotene and Golimumab. Rheumatoid arthritis [FA20] [140]
Dexamethasone DMMWZET Moderate Increased metabolism of Bexarotene caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [40]
Nafcillin DMN9RPO Minor Increased metabolism of Bexarotene caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [36]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Bexarotene and Leflunomide. Rheumatoid arthritis [FA20] [88]
Aripiprazole DM3NUMH Moderate Increased metabolism of Bexarotene caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [141]
Fentanyl DM8WAHT Moderate Increased metabolism of Bexarotene caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [38]
Sufentanil DMU7YEL Moderate Increased metabolism of Bexarotene caused by Sufentanil mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [40]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Bexarotene when combined with Anthrax vaccine. Sepsis [1G40-1G41] [142]
Avanafil DM75CXN Moderate Increased metabolism of Bexarotene caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [143]
Tadalafil DMJZHT1 Moderate Increased metabolism of Bexarotene caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [40]
LDE225 DMM9F25 Moderate Increased metabolism of Bexarotene caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [144]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Bexarotene caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [40]
Gefitinib DM15F0X Moderate Increased metabolism of Bexarotene caused by Gefitinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [101]
Larotrectinib DM26CQR Moderate Increased metabolism of Bexarotene caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [33]
Methylprednisolone DM4BDON Moderate Increased metabolism of Bexarotene caused by Methylprednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [40]
Vinblastine DM5TVS3 Moderate Increased metabolism of Bexarotene caused by Vinblastine mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [40]
Docetaxel DMDI269 Moderate Increased metabolism of Bexarotene caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [40]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Bexarotene and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [40]
Armodafinil DMGB035 Moderate Increased metabolism of Bexarotene caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [122]
LEE011 DMMX75K Moderate Increased metabolism of Bexarotene caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [33]
Etoposide DMNH3PG Moderate Increased metabolism of Bexarotene caused by Etoposide mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [40]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of Bexarotene and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [33]
Prednisolone DMQ8FR2 Moderate Increased metabolism of Bexarotene caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [40]
Norethindrone DMTY169 Major Increased metabolism of Bexarotene caused by Norethindrone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [62]
Taxol DMUOT9V Moderate Increased metabolism of Bexarotene caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [145]
Doxorubicin DMVP5YE Moderate Increased metabolism of Bexarotene caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [40]
Vinorelbine DMVXFYE Moderate Increased metabolism of Bexarotene caused by Vinorelbine mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [40]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Bexarotene and Naltrexone. Substance abuse [6C40] [146]
Fostamatinib DM6AUHV Moderate Increased metabolism of Bexarotene caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [147]
Apixaban DM89JLN Moderate Increased metabolism of Bexarotene caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [148]
Brilinta DMBR01X Moderate Increased metabolism of Bexarotene caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [85]
Cabozantinib DMIYDT4 Moderate Increased metabolism of Bexarotene caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [149]
Sirolimus DMGW1ID Moderate Increased metabolism of Bexarotene caused by Sirolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [33]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Bexarotene and Azathioprine. Transplant rejection [NE84] [33]
Tacrolimus DMZ7XNQ Moderate Increased metabolism of Bexarotene caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [33]
Elagolix DMB2C0E Moderate Increased metabolism of Bexarotene caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [150]
Astemizole DM2HN6Q Moderate Increased metabolism of Bexarotene caused by Astemizole mediated induction of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [40]
Triamcinolone DM98IXF Moderate Increased metabolism of Bexarotene caused by Triamcinolone mediated induction of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [40]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Bexarotene and Ganciclovir. Virus infection [1A24-1D9Z] [33]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Bexarotene and Valganciclovir. Virus infection [1A24-1D9Z] [33]
⏷ Show the Full List of 253 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20 E00664 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Bexarotene 75 mg capsule 75 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2807).
2 Emerging drugs in cutaneous T cell lymphoma. Expert Opin Emerg Drugs. 2008 Jun;13(2):345-61.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
8 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
9 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
10 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
11 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
12 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
13 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
14 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
15 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
16 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
18 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
19 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
20 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
21 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
22 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
23 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
24 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
25 Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
26 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
27 Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403.
28 The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15(8):1360-9.
29 Phytanic acid is a retinoid X receptor ligand. Eur J Biochem. 1996 Feb 15;236(1):328-33.
30 Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature. 2002 Jan 10;415(6868):187-92.
31 Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators thro... J Biol Chem. 2005 Jan 14;280(2):1625-33.
32 Activation of mammalian retinoid X receptors by the insect growth regulator methoprene. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6157-60.
33 Cerner Multum, Inc. "Australian Product Information.".
34 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
35 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
36 Product Information. Targretin (bexarotene) Ligand Pharmaceuticals, San Diego, CA.
37 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
38 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
39 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
40 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
41 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
42 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
43 Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153]
44 Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748]
45 Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
46 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
47 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
48 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
49 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
50 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
51 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
52 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
53 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
54 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
55 Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
56 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
57 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
58 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
59 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
60 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
61 Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
62 Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
63 Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
64 Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
65 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
66 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
67 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
68 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
69 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
70 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
71 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
72 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
73 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
74 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
75 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
76 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
77 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
78 Product Information. Cancidas (caspofungin) Merck & Co, Inc, West Point, PA.
79 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
80 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
81 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
82 Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53. [PMID: 9164416]
83 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
84 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
85 Canadian Pharmacists Association.
86 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
87 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
88 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
89 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
90 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
91 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
92 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
93 Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA.
94 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
95 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
96 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
97 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
98 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
99 Cerner Multum, Inc. "Canadian Product Information.".
100 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
101 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
102 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
103 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
104 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
105 Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.
106 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
107 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
108 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
109 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
110 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
111 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
112 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
113 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
114 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
115 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
116 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
117 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
118 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
119 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
120 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
121 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
122 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
123 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
124 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
125 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
126 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
127 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
128 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
129 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
130 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
131 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
132 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
133 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
134 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
135 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
136 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
137 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
138 Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
139 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
140 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
141 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
142 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
143 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
144 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
145 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
146 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
147 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
148 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
149 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
150 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.